OVARIAN CANCER and US: RFI

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label RFI. Show all posts
Showing posts with label RFI. Show all posts

Sunday, May 08, 2011

abstract: A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian - GOG



Note: although a 3% difference of estimated recurrence rates (542 patients @ 3% = 16.26 patients/lives), the abstract does not allow for a description of the patient demographics eg. cell type, stage..., note also that as in past blogs the GOG studies include stage 1 and stage 11

OBJECTIVE:

To compare the recurrence-free interval (RFI) and safety profile in patients with completely resected high-risk early-stage ovarian cancer treated with intravenous (IV) carboplatin and paclitaxel with or without maintenance low-dose paclitaxel for 24weeks.

METHODS:

Eligibility was limited to patients with stage IA/B (grade 3 or clear cell), all IC or II epithelial ovarian cancer. All patients were to receive carboplatin AUC 6 and paclitaxel 175mg/m(2) q3 weeks×3 courses with random assignment to either observation or maintenance paclitaxel 40mg/m(2)/week×24weeks. Recurrence required clinical or radiological evidence of new tumor.

RESULTS:

There were 571 patients enrolled onto this study, of whom 29 were deemed ineligible due to inappropriate stage or pathology, leaving 542 patients. At least 3 cycles of treatment were administered to 524/542 (97%) of patients, and among those assigned to maintenance paclitaxel, 80% completed the regimen. The incidence of grade 2 or worse peripheral neuropathy (15.5% vs. 6%), infection/fever (19.9% vs. 8.7%), and dermatologic events (70.8% vs. 52.1%) was higher on the maintenance regimen (p<0.001). The cumulative probability of recurring within 5years for the maintenance paclitaxel regimen is 20% vs. 23% for surveillance (hazard ratio 0.807; 95% CI: 0.565-1.15). The probability of surviving 5years was 85.4% and 86.2%, respectively.

CONCLUSION:

Maintenance paclitaxel at 40mg/m(2)/week×24weeks added to standard dose AUC6 and paclitaxel 175mg/m(2)×3 doses provides no significant increase in RFI.